Skip to main content
Fig. 8 | Alzheimer's Research & Therapy

Fig. 8

From: CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease

Fig. 8

AAV-CERTL reduces microglia reactivity to Iba1 and CD86 expression levels but has no significant effect on GFAP immunoreactivity in the cortex of 5xFAD mice. a Representative photomicrograph of Iba1 staining in the cortical motor sensory region of 5xFAD animals treated with AAV-control or AAV-CERTL (scale bar 50 μm). b Densitometric analysis of Iba1 staining represented as a percentage of the area (AAV-control n = 6 and AAV-CERTL n = 4 for WT and 5xFAD groups). c Densitometric analysis of Iba1 staining represented as number of positive Iba1 cells/mm2 (AAV-control n = 6 and AAV-CERTL n = 4 for 5xFAD groups). d Length of microglia ramification and sphericity per cell in AAV-control or AAV-CERTL. Morphological analysis was performed on 3–5 pictures/group. e Illustrations of the microglia morphological analysis applied to a fluorescent photomicrograph captured with × 60 objective with a single cell cropped to show details. Scale bar = 20. f Analysis of gene expression of membrane markers CD86 (4–5 number of animals per group). g Representative photomicrographs of GFAP staining in the cortical motor sensory region of 5xFAD animals treated with AAV-control or AAV-CERTL (scale bar 50 μm). h Densitometric analysis of GFAP staining represented as a percentage of the area (AAV-control n = 6 and AAV-CERTL n = 4 for WT and 5xFAD groups). Bars represent the mean ± S.E.M per group (two-way ANOVA, LSD, significant effects, *p < 0.05; **p < 0.01)

Back to article page